Alzinova
Correction: Alzinova publishes annual report for 2024
Due to technical problems, the Annual Report was not included as an appendix in the original press release which is why the press release is being resented as a correction with the Annual Report attached.
Alzinova AB (publ) (“Alzinova” or the “Company”) hereby publishes its annual report for the financial year 2024. The annual report, which is attached to the press release, can also be downloaded from the Company's website, https://www.alzinova.com/investors/financial-reports/.
For more information, please contact:
Tord Labuda, CEO
E-mail: info@alzinova.com
Erik Kullgren, CFO
E-mail: info@alzinova.com
About Alzinova AB
Alzinova AB is a Swedish biopharmaceutical company in clinical development specializing in the treatment of Alzheimer's disease, where the starting point is to attack toxic amyloid-beta oligomers. The lead candidate ALZ-101 is a therapeutic vaccine against Alzheimer's disease. Alzinova's patented AβCC peptide technology makes it possible to develop disease-modifying treatments that target the toxic amyloid-beta oligomers that are central to the onset and development of the disease with great accuracy. From a global perspective, Alzheimer's disease is one of the most common and devastating neurological diseases, with around 40 million affected today. Based on the same technology, the company is also developing the antibody ALZ-201, which is currently in preclinical development, and the goal is to further expand the pipeline. The company's Certified Adviser on Nasdaq First North Growth Market is Mangold Fondkommission AB. For more information about Alzinova, please visit: www.alzinova.com
| Datum | 2025-04-24, kl 14:34 |
| Källa | MFN |
Ungdomsdeal - 200 kr ! Just nu får alla nya kunder mellan 18 och 25 år 200 kr gratis när man skapar konto på Nordnet, insatt i fonden Nordnet One Balanserad. Bra läge att testa Nordnet!